CE
Clark Estates Inc
13F filer · CIK 0001056466Reported Aug 5, 2026
Net seller this quarter
13F portfolio value$434MU.S. long equity reported on 13F
Positions8610 new · 18 closed
Net flow last quarter-$19.3MBuys minus sells
Top 10 positions weight36.2%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 5, 202686 positions | |||||
| $22.2M | 5.13% | 0.02% | +21.3% | Q4 2016 | |
| $19.3M | 4.44% | 0.01% | Not reported | Q2 2025 | |
| $17.3M | 3.99% | 0.06% | +14.0% | Q3 2025 | |
| $16.5M | 3.82% | 0.01% | +19.3% | Q3 2024 | |
| $15.9M | 3.66% | 0.02% | +21.4% | Q3 2022 | |
| $15.4M | 3.56% | 0.12% | -31.0% | Q1 2024 | |
| $14.6M | 3.36% | 0.25% | +6.8% | Q3 2022 | |
| $14.5M | 3.34% | 50046.77% | -17.7% | Q4 2025 | |
| $11.3M | 2.60% | 0.12% | +1587.5% | Q1 2026 | |
| $10.1M | 2.32% | 0.03% | -45.2% | Q1 2025 | |
| $9.93M | 2.29% | 1.42% | -3.1% | Q4 2020 | |
| $7.04M | 1.62% | 0.01% | -41.9% | Q3 2014 | |
| $4.58M | 1.06% | 0.16% | +40.9% | Q3 2023 | |
| $4.28M | 0.99% | 0.97% | Not reported | Q2 2013 | |
| $4.13M | 0.95% | 0.02% | -34.8% | Q1 2023 | |
| $3.88M | 0.89% | 0.19% | +18.6% | Q2 2013 | |
| $3.79M | 0.87% | 0.08% | Not reported | Q3 2024 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $3.58M | 0.83% | 0.09% | Not reported | Q3 2023 |
| $3.51M | 0.81% | 0.04% | Not reported | Q4 2024 | |
| $3.5M | 0.81% | 0.00% | Not reported | Q1 2014 | |
| $3.49M | 0.80% | 0.06% | Not reported | Q1 2022 | |
| $3.32M | 0.76% | 0.02% | Not reported | Q1 2016 | |
| $3.31M | 0.76% | 0.01% | Not reported | Q2 2018 | |
| $3.29M | 0.76% | 0.00% | Not reported | Q1 2015 | |
| $3.27M | 0.75% | 0.18% | -10.4% | Q1 2018 | |
| $3.24M | 0.75% | 0.19% | +53.3% | Q4 2020 | |
| $3.08M | 0.71% | 0.06% | +44.4% | Q1 2023 | |
| $3.04M | 0.70% | 0.09% | -10.3% | Q3 2014 | |
| $3.02M | 0.70% | 0.18% | Not reported | Q4 2025 | |
| $2.96M | 0.68% | 0.14% | Not reported | Q1 2025 | |
| $2.95M | 0.68% | 0.05% | Not reported | Q2 2024 | |
| $2.89M | 0.67% | 0.03% | New | Q2 2026 | |
| $2.87M | 0.66% | 0.07% | Not reported | Q1 2026 | |
| $2.85M | 0.66% | 0.03% | Not reported | Q1 2024 | |
| $2.83M | 0.65% | 0.01% | Not reported | Q2 2024 | |
| $2.81M | 0.65% | 0.01% | -0.9% | Q4 2019 | |
| $2.81M | 0.65% | 0.15% | New | Q2 2026 | |
| $2.72M | 0.63% | 0.01% | Not reported | Q4 2020 | |
| $2.65M | 0.61% | 0.05% | Not reported | Q2 2016 | |
| $2.6M | 0.60% | 0.11% | New | Q2 2026 | |
| $2.57M | 0.59% | 0.01% | Not reported | Q1 2026 | |
| $2.54M | 0.59% | 0.48% | Not reported | Q3 2025 | |
| $2.48M | 0.57% | 0.00% | Not reported | Q1 2020 | |
| $2.47M | 0.57% | 0.08% | New | Q2 2026 | |
| $2.46M | 0.57% | 0.09% | +68.4% | Q1 2025 | |
| $2.45M | 0.56% | 0.07% | Not reported | Q3 2019 | |
| $2.4M | 0.55% | 0.19% | Not reported | Q4 2020 | |
| $2.39M | 0.55% | 0.05% | +31.8% | Q3 2014 | |
| $2.33M | 0.54% | 0.00% | Not reported | Q2 2013 | |
| $2.33M | 0.54% | 0.01% | New | Q2 2026 | |
| Q1 2026Reported May 11, 202694 positions | |||||
| $19.3M | 4.63% | 0.01% | +25.0% | Q2 2025 | |
| $18.9M | 4.55% | 0.17% | +34.9% | Q1 2024 | |
| $17.4M | 4.17% | 0.01% | +90.6% | Q4 2016 | |
| $16.6M | 3.99% | 60804.49% | +136.4% | Q4 2025 | |
| $16.2M | 3.90% | 0.06% | +58.1% | Q1 2025 | |
| $16M | 3.84% | 0.05% | -12.3% | Q3 2025 | |
| $14.3M | 3.44% | 0.01% | +176.6% | Q3 2024 | |
| $14M | 3.37% | 0.02% | -22.2% | Q3 2022 | |
| $13.4M | 3.23% | 0.01% | Not reported | Q3 2014 | |
| $13.1M | 3.15% | 0.23% | Not reported | Q3 2022 | |
| AMAVNSAvanos Medical, Inc. | $11.8M | 2.84% | 1.81% | -4.9% | Q1 2025 |
| $9.49M | 2.28% | 1.95% | Not reported | Q4 2020 | |
| $6.99M | 1.68% | 0.03% | -26.7% | Q1 2023 | |
| $3.63M | 0.87% | 0.00% | Not reported | Q1 2015 | |
| $3.21M | 0.77% | 0.00% | Not reported | Q1 2014 | |
| $3.19M | 0.77% | 0.06% | Not reported | Q2 2024 | |
| $2.92M | 0.70% | 0.19% | Not reported | Q1 2018 | |
| $2.92M | 0.70% | 0.02% | Not reported | Q1 2021 | |
| $2.9M | 0.70% | 0.04% | Not reported | Q4 2024 | |
| $2.83M | 0.68% | 0.12% | Not reported | Q3 2023 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $2.82M | 0.68% | 0.09% | Not reported | Q3 2023 |
| $2.81M | 0.68% | 0.07% | Not reported | Q3 2024 | |
| $2.8M | 0.67% | 0.01% | Not reported | Q2 2018 | |
| $2.76M | 0.66% | 0.16% | Not reported | Q2 2013 | |
| $2.72M | 0.65% | 0.00% | Not reported | Q2 2013 | |
| $2.67M | 0.64% | 0.97% | Not reported | Q2 2013 | |
| $2.61M | 0.63% | 0.00% | Not reported | Q1 2020 | |
| $2.56M | 0.62% | 0.01% | Not reported | Q4 2019 | |
| $2.55M | 0.61% | 0.11% | Not reported | Q3 2023 | |
| $2.5M | 0.60% | 0.11% | Not reported | Q3 2014 | |
| $2.4M | 0.58% | 0.06% | +15.1% | Q1 2022 | |
| $2.38M | 0.57% | 0.03% | +14.6% | Q2 2013 | |
| $2.35M | 0.57% | 0.01% | Not reported | Q2 2024 | |
| $2.33M | 0.56% | 0.02% | Not reported | Q1 2025 | |
| $2.32M | 0.56% | 0.01% | Not reported | Q4 2020 | |
| $2.32M | 0.56% | 0.07% | Not reported | Q3 2019 | |
| $2.31M | 0.56% | 0.04% | Not reported | Q1 2023 | |
| $2.3M | 0.55% | 0.03% | +15.4% | Q1 2024 | |
| $2.29M | 0.55% | 0.12% | Not reported | Q4 2020 | |
| $2.28M | 0.55% | 0.14% | +20.8% | Q1 2025 | |
| $2.25M | 0.54% | 0.04% | Not reported | Q1 2022 | |
| $2.23M | 0.54% | 0.03% | +26.7% | Q2 2024 | |
| $2.21M | 0.53% | 0.01% | New | Q1 2026 | |
| $2.19M | 0.53% | 0.07% | New | Q1 2026 | |
| $2.19M | 0.53% | 0.00% | New | Q1 2026 | |
| $2.18M | 0.52% | 0.01% | +44.0% | Q2 2020 | |
| $2.17M | 0.52% | 0.08% | Not reported | Q1 2025 | |
| $2.15M | 0.52% | 0.04% | Not reported | Q2 2021 | |
| $2.15M | 0.52% | 0.02% | Not reported | Q2 2013 | |
| $2.15M | 0.52% | 0.08% | Not reported | Q2 2013 | |
| Q4 2025Reported Feb 12, 202695 positions | |||||
| $18.2M | 4.42% | 0.01% | +28.0% | Q2 2025 | |
| $18.2M | 4.42% | 0.02% | Not reported | Q3 2022 | |
| $17.6M | 4.26% | 0.06% | +8.3% | Q3 2025 | |
| $17M | 4.13% | 0.12% | +38.7% | Q1 2024 | |
| $14.9M | 3.61% | 0.01% | -31.1% | Q3 2014 | |
| $14.1M | 3.42% | 0.23% | -4.1% | Q3 2022 | |
| $13.6M | 3.29% | 0.04% | -47.7% | Q1 2025 | |
| $10.9M | 2.64% | 0.55% | +46.3% | Q4 2015 | |
| $10.5M | 2.54% | 0.01% | +0.1% | Q4 2016 | |
| AMAVNSAvanos Medical, Inc. | $9.98M | 2.42% | 1.91% | +13.4% | Q1 2025 |
| $9.84M | 2.39% | 0.03% | -7.7% | Q1 2023 | |
| $8.43M | 2.05% | 25724.98% | New | Q4 2025 | |
| $6.4M | 1.55% | 0.00% | Not reported | Q3 2024 | |
| $5.89M | 1.43% | 0.01% | -39.4% | Q3 2025 | |
| $5.39M | 1.31% | 2.33% | Not reported | Q4 2020 | |
| $3.31M | 0.80% | 0.07% | -39.9% | Q3 2024 | |
| $3.19M | 0.78% | 0.00% | Not reported | Q1 2015 | |
| $3.02M | 0.73% | 0.04% | Not reported | Q4 2024 | |
| $2.97M | 0.72% | 0.11% | Not reported | Q3 2014 | |
| $2.8M | 0.68% | 0.00% | Not reported | Q1 2014 | |
| $2.8M | 0.68% | 0.07% | Not reported | Q2 2024 | |
| $2.76M | 0.67% | 0.16% | -24.7% | Q2 2013 | |
| $2.75M | 0.67% | 0.04% | Not reported | Q1 2020 | |
| $2.69M | 0.65% | 0.01% | Not reported | Q2 2018 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $2.66M | 0.65% | 0.09% | Not reported | Q3 2023 |
| $2.63M | 0.64% | 0.04% | Not reported | Q4 2018 | |
| $2.61M | 0.63% | 0.08% | Not reported | Q1 2025 | |
| $2.6M | 0.63% | 0.02% | Not reported | Q1 2021 | |
| $2.53M | 0.61% | 0.04% | Not reported | Q1 2022 | |
| $2.52M | 0.61% | 0.12% | Not reported | Q1 2025 | |
| $2.51M | 0.61% | 1.10% | Not reported | Q2 2013 | |
| $2.49M | 0.61% | 0.00% | Not reported | Q3 2025 | |
| $2.47M | 0.60% | 0.01% | -28.5% | Q2 2024 | |
| $2.45M | 0.59% | 0.18% | +13.2% | Q1 2018 | |
| $2.44M | 0.59% | 0.03% | Not reported | Q1 2020 | |
| $2.41M | 0.58% | 0.00% | +8.0% | Q2 2013 | |
| $2.41M | 0.58% | 0.12% | Not reported | Q3 2023 | |
| $2.38M | 0.58% | 0.01% | Not reported | Q1 2024 | |
| $2.35M | 0.57% | 0.12% | +13.5% | Q4 2019 | |
| $2.34M | 0.57% | 0.05% | Not reported | Q1 2025 | |
| $2.32M | 0.56% | 0.00% | Not reported | Q1 2020 | |
| $2.29M | 0.56% | 0.01% | +12.7% | Q1 2017 | |
| $2.29M | 0.56% | 0.08% | +60.8% | Q2 2013 | |
| $2.28M | 0.55% | 0.04% | +14.0% | Q1 2025 | |
| $2.28M | 0.55% | Not reported | +12.7% | Q1 2021 | |
| $2.27M | 0.55% | 0.47% | +13.5% | Q3 2025 | |
| TTGNATegna Inc | $2.26M | 0.55% | Not reported | Not reported | Q4 2015 |
| $2.26M | 0.55% | 0.04% | Not reported | Q2 2021 | |
| $2.25M | 0.55% | 0.04% | +13.5% | Q1 2023 | |
| $2.25M | 0.55% | 0.02% | Not reported | Q2 2013 | |
| Q3 2025Reported Nov 10, 202596 positions | |||||
| $21.9M | 5.00% | 0.07% | -25.8% | Q1 2025 | |
| $21.4M | 4.90% | 0.02% | -10.0% | Q3 2014 | |
| $19.4M | 4.43% | 0.03% | +113.8% | Q1 2022 | |
| $16.1M | 3.69% | 0.02% | Not reported | Q3 2022 | |
| $14.6M | 3.33% | 0.05% | New | Q3 2025 | |
| $14.3M | 3.27% | 0.01% | Not reported | Q2 2025 | |
| $13M | 2.96% | 0.24% | +1.2% | Q3 2022 | |
| $11.8M | 2.69% | 0.04% | -51.9% | Q1 2023 | |
| $11.3M | 2.59% | 0.09% | Not reported | Q1 2024 | |
| $11M | 2.51% | 0.00% | -20.7% | Q4 2024 | |
| $10.7M | 2.44% | 0.01% | Not reported | Q4 2016 | |
| $10.6M | 2.42% | 0.37% | +57.7% | Q4 2015 | |
| AMAVNSAvanos Medical, Inc. | $9.06M | 2.07% | 1.69% | +58.7% | Q1 2025 |
| $8.33M | 1.90% | 0.01% | New | Q3 2025 | |
| $7.2M | 1.64% | 0.00% | -37.5% | Q3 2024 | |
| $4.55M | 1.04% | 0.04% | -75.2% | Q4 2024 | |
| $4.11M | 0.94% | 1.11% | Not reported | Q2 2013 | |
| $4.06M | 0.93% | 0.06% | -13.8% | Q1 2022 | |
| $3.7M | 0.85% | 0.12% | -24.6% | Q3 2024 | |
| $3.53M | 0.81% | 2.34% | Not reported | Q4 2020 | |
| HSHSIIHeidrick & Struggles International Inc | $3.35M | 0.77% | 0.32% | Not reported | Q2 2017 |
| $3.29M | 0.75% | 0.04% | Not reported | Q4 2024 | |
| $3.21M | 0.73% | 0.00% | Not reported | Q1 2014 | |
| $2.96M | 0.68% | 0.02% | Not reported | Q2 2024 | |
| $2.89M | 0.66% | 0.00% | Not reported | Q1 2015 | |
| $2.87M | 0.66% | 0.20% | Not reported | Q2 2013 | |
| $2.83M | 0.65% | 0.02% | Not reported | Q1 2021 | |
| $2.82M | 0.64% | 0.02% | +10.3% | Q1 2018 | |
| $2.55M | 0.58% | 0.04% | Not reported | Q2 2021 | |
| AWAMWDAmerican Woodmark Corp | $2.52M | 0.58% | 0.26% | +13.6% | Q2 2019 |
| $2.52M | 0.57% | 0.03% | Not reported | Q1 2020 | |
| $2.48M | 0.57% | 0.05% | Not reported | Q1 2025 | |
| $2.48M | 0.57% | 0.41% | New | Q3 2025 | |
| $2.46M | 0.56% | 0.04% | Not reported | Q1 2022 | |
| TTGNATegna Inc | $2.37M | 0.54% | Not reported | Not reported | Q4 2015 |
| $2.35M | 0.54% | 0.15% | +5.6% | Q1 2018 | |
| $2.32M | 0.53% | 0.09% | Not reported | Q3 2023 | |
| $2.31M | 0.53% | 0.04% | Not reported | Q4 2018 | |
| $2.3M | 0.52% | 0.12% | Not reported | Q3 2023 | |
| $2.29M | 0.52% | 0.03% | Not reported | Q1 2024 | |
| $2.29M | 0.52% | 0.06% | Not reported | Q4 2024 | |
| $2.28M | 0.52% | 0.00% | +9.8% | Q2 2013 | |
| $2.28M | 0.52% | 0.02% | Not reported | Q3 2017 | |
| $2.27M | 0.52% | Not reported | +6.0% | Q1 2025 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $2.24M | 0.51% | 0.09% | Not reported | Q3 2023 |
| $2.24M | 0.51% | 0.10% | New | Q3 2025 | |
| $2.23M | 0.51% | 0.00% | New | Q3 2025 | |
| $2.22M | 0.51% | 0.02% | Not reported | Q2 2024 | |
| $2.18M | 0.50% | Not reported | New | Q3 2025 | |
| $2.15M | 0.49% | 0.06% | Not reported | Q2 2024 | |
Premium opens every quarter this fund has filed